http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102184153-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16141 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K17-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005 |
| filingDate | 2019-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102184153-B1 |
| titleOfInvention | Polymer scaffold-based influenza virus-like particle vaccine and method for manufacturing the same |
| abstract | The present invention includes a polymer nanoparticle having a plurality of first functional groups on the surface, and a plurality of proteins having a second functional group linked to the c-terminus having a second functional group binding to the first functional group, and a part of the protein or All contain hemagglutinin (HA); The hemagglutinin is linked to a polymer nanoparticle through a combination of a first functional group and a second functional group, and relates to an influenza vaccine, an influenza virus-like structure. The influenza-like construct according to the present invention is administered to an individual to induce humoral immunity and cellular immunity at high levels without a separate immune enhancing agent, and does not show toxicity in the body. In addition, the influenza vaccine has an advantage of low manufacturing cost and rapid mass production. Further, an influenza virus-like construct vaccine in which an antigen other than hemagglutinin is labeled on its surface can be effectively used as a vaccine against such antigens other than influenza. |
| priorityDate | 2019-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 241.